SJEPD031111_D1.RNA-Seq
EPN · EPN Tumor
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- EPN
- cancer_type_detailed
- —
- subtype
- EPN Tumor
- cancer_type
- EPN
- subtype
- EPN Tumor
- e1_e2
- E1
- umap1_2d
- -2.26892437
- umap2_2d
- 3.284817358
- umap1_3d
- 0.041744056
- umap2_3d
- 2.21225301
- umap3_3d
- -2.05255551
- dataset
- EPN-StJude
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- KRAS_SIGNALING_DN+0.360
- APICAL_SURFACE+0.250
- INFLAMMATORY_RESPONSE+0.250
- KRAS_SIGNALING_UP+0.220
- BILE_ACID_METABOLISM+0.190
- HEDGEHOG_SIGNALING+0.190
- ALLOGRAFT_REJECTION+0.170
- COMPLEMENT+0.170
- SPERMATOGENESIS+0.130
- ESTROGEN_RESPONSE_EARLY+0.110
Top 10 suppressed
- MYC_TARGETS_V1-0.660
- E2F_TARGETS-0.630
- DNA_REPAIR-0.590
- G2M_CHECKPOINT-0.560
- MYC_TARGETS_V2-0.540
- UNFOLDED_PROTEIN_RESPONSE-0.540
- WNT_BETA_CATENIN_SIGNALING-0.490
- CHOLESTEROL_HOMEOSTASIS-0.450
- MTORC1_SIGNALING-0.450
- GLYCOLYSIS-0.370
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
2 twins match this tumor's tissue · 8 come from a different tissue of origin ← cross-tissue dominant
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | BS_TCGEZJ5F | EPN | Supratentorial EPN | 0.905 |
| 2 | MDT-AP-2913 | Med | Medulloblastoma | 0.900 |
| 3 | BS_QF5VVZX5 | Ganglioglioma | — | 0.896 |
| 4 | TCGA-97-8552-01A-11R-2403-07 | — | cohortA1 | 0.896 |
| 5 | SRR1485652 | GTEX | — | 0.893 |
| 6 | BS_0X9EGHY2 | low-grade glioma | — | 0.888 |
| 7 | MDT-AP-0208 | Med | Medulloblastoma | 0.884 |
| 8 | BS_398KYV92 | Meningioma | — | 0.882 |
| 9 | BS_YZ2Z1Q6Y | pilocytic astrocytoma | — | 0.881 |
| 10 | BS_ZR96A4FH | DNET | — | 0.881 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 18 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| KRAS_SIGNALING_DN | 0.360 | Remibrutinib | — uncovered |
| APICAL_SURFACE | 0.250 | Temsirolimus | — uncovered |
| INFLAMMATORY_RESPONSE | 0.250 | Idelalisib | — uncovered |
| KRAS_SIGNALING_UP | 0.220 | Inavolisib | — uncovered |
| BILE_ACID_METABOLISM | 0.190 | Inavolisib | — uncovered |
| HEDGEHOG_SIGNALING | 0.190 | Inavolisib | — uncovered |
| ALLOGRAFT_REJECTION | 0.170 | Idelalisib | — uncovered |
| COMPLEMENT | 0.170 | Inavolisib | — uncovered |
| SPERMATOGENESIS | 0.130 | Inavolisib | — uncovered |
| ESTROGEN_RESPONSE_EARLY | 0.110 | Inavolisib | — uncovered |
| MYOGENESIS | 0.110 | Inavolisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.100 | Inavolisib | — uncovered |
| COAGULATION | 0.090 | Binimetinib | — uncovered |
| HEME_METABOLISM | 0.060 | Temsirolimus | — uncovered |
| IL2_STAT5_SIGNALING | 0.060 | Idelalisib | — uncovered |
| PANCREAS_BETA_CELLS | 0.050 | Cobimetinib | — uncovered |
| UV_RESPONSE_DN | 0.050 | Inavolisib | — uncovered |
| ESTROGEN_RESPONSE_LATE | 0.030 | Idelalisib | — uncovered |